Article

Efficacy of combined photodynamic and hyperthermic therapy with a new light source in an in vivo osteosarcoma tumor model.

Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Mie University, Tsu, Japan.
Journal of Clinical Laser Medicine & Surgery 03/2004; 22(1):3-8. DOI: 10.1089/104454704773660903
Source: PubMed

ABSTRACT In this study, we investigated the efficacy of Super Lizer (SL) as a new light source in photodynamic therapy (PDT) with hyperthermia in an in vivo osteosarcoma tumor model.
Nude mice in three study groups (PDT only, PDT with hyperthermia in low energy, and PDT with hyperthermia in high energy) and three control groups (no treatment, photosensitizer only, and hyperthermia only) were implanted subcutaneously with human osteosarcoma cells and injected with a photosensitizing hematoporphyrin derivative (HPD) at a total dose of 10 mg/kg, in all study groups and in control group 2. At 72 h after light treatment, mice were sacrificed.
The tumor volume growth rates in the heat-only (1.50) and PDT-only (1.40) groups were significantly lower than the growth rate in the no-treatment group (1.82). Further, the tumor volume growth rate in the PDT with hyperthermia in high-energy group (1.19) was significantly lower than in the heat- or PDT-only groups.
Although non-laser PDT, including SL-PDT, may be beneficial only in the treatment of superficial tumors because of limited light penetration, PDT combined with hyperthermia may extend the utility of PDT in antitumor treatment. The use of SL as a new light source in PDT may significantly advance antitumor therapy due to its simplicity, ease, and cost benefit.

1 Bookmark
 · 
53 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Photodynamic therapy uses nonthermal coherent light delivered via fiber optic cable to locally activate a photosensitive chemotherapeutic agent that ablates tumor tissue. Owing to the limitations of light penetration, it is unknown whether photodynamic therapy can treat large osseous tumors. We determined whether photodynamic therapy can induce necrosis in large osseous tumors, and if so, to quantify the volume of treated tissue. In a pilot study we treated seven dogs with spontaneous osteosarcomas of the distal radius. Tumors were imaged with MRI before and 48 hours after treatment, and the volumes of hypointense regions were compared. The treated limbs were amputated immediately after imaging at 48 hours and sectioned corresponding to the MR axial images. We identified tumor necrosis histologically; the regions of necrosis corresponded anatomically to hypointense tissue on MRI. The mean volume of necrotic tissue seen on MRI after photodynamic therapy was 21,305 mm(3) compared with a pretreatment volume of 6108 mm(3). These pilot data suggest photodynamic therapy penetrates relatively large canine osseous tumors and may be a useful adjunct for treatment of bone tumors.
    Clinical Orthopaedics and Related Research 02/2009; 467(4):1028-34. · 2.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we investigated whether or not griseofulvin (GF), which is an antimycotic widely used for the oral treatment of skin fungal infections, enhanced the effect of aminolevulinic acid-based photodynamic therapy (ALA-PDT) in vitro, using several tumor cell lines. A human squamous cell carcinoma line (KB), two human osteosarcoma cell lines from mandible (HOSM-1, HOSM-2), and the human gingiva-derived fibroblast line (HF), representing normal cells, were used. GF enhancement of ALA-PDT was evaluated by comparing the effect of ALAin combination with GF to the effect of ALAalone (GF enhancement rate of ALA-PDT). Also, the effect of GF on intracellular accumulation of protoporphyrin IX (PpIX) was evaluated by comparing the intracellular accumulation of PpIX in the ALA and GF combined treatment with that of ALA treatment alone (pGF enhancement rate of intracellular PpIX). GFenhancement rate of ALA-PDT was 2.51 in KB cells, and 1.65 and 1.27 in HOSM-1 and HOSM-2 cells, respectively. GF enhancement rates of intracellular PpIX were 1.94 in KB cells, 1.53 in HOSM-1 cells, and 1.19 in HOSM-2 cells. GF enhancement rate of intracellular PpIX followed the same trends as the levels of GF enhancement rate of ALA-PDT in the different cell types. For HF, a large effect was not revealed in this study. The present study, although preliminary, strongly suggests that concomitant treatment with ALAand GF may be very useful to enhance the effect of ALA-PDT.
    Photomedicine and Laser Surgery 05/2006; 24(2):186-91. · 1.63 Impact Factor